Skip to content

Study · Animal study (in vivo) · rat · 2020

1 result

GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats.

Maruta K, Takajo T, Akiba Y, Said H, Irie E, Kato I, Kuwahara A, Kaunitz JD

Digestive diseases and sciences31 Jan 2020Cited by 22 (Europe PMC)

PMID32006214 (opens in a new tab)PMCIDPMC7392813 (opens in a new tab)DOI10.1007/s10620-020-06097-6 (opens in a new tab)PepBankPUB-32006214
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In LPS-treated rats, teduglutide given 3 or 6 hours after LPS reduced FD4 uptake measured 6 hours after LPS.

    In plain wordsIn rats, teduglutide given 3 or 6 hours after LPS reduced intestinal FD4 uptake measured at 6 hours.

    Peptide
    Teduglutide
    Outcome
    DecreaseFD4 uptake after LPS
    Study

    ratn: not reported in source

    LPS-treated rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    FD4 uptake measured 6 h after LPS was reduced by TDG 3 or 6 h after LPS treatment.
    2 context sentences
    Summary · context
    We assessed small intestinal paracellular permeability in vivo by measuring the appearance of intraduodenally perfused FITC-dextran 4000 (FD4) into the portal vein (PV) in rats 1-24 h after LPS treatment (5 mg/kg, ip).
    Summary · context
    We also examined the effect of a stable GLP-2 analog teduglutide (TDG) on FD4 permeability.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.